Please wait while the formulary information is being retrieved.
OXYMORPHONE HCL (oxymorphone HCl)
- Acute pain
oxymorphone 10 mg tablet
- 1 tablet (10 mg) by oral route every 6 hours on an empty stomach
oxymorphone 5 mg tablet
- 1 tablet (5 mg) by oral route every 4-6 hours on an empty stomach
10 mg tablet
- 1 tablet (10 mg) by oral route every 6 hours on an empty stomach
5 mg tablet
- 1 tablet (5 mg) by oral route every 4-6 hours on an empty stomach
Acute pain
- 1 tablet (5 mg) by oral route every 6 hours on an empty stomach
- 1 tablet (5 mg) by oral route every 4 hours on an empty stomach
- 1 tablet (5 mg) by oral route every 4-6 hours on an empty stomach
- 2 tablets (10 mg) by oral route every 4-6 hours on an empty stomach
- 1 tablet (10 mg) by oral route every 4 hours on an empty stomach
- 1 tablet (10 mg) by oral route every 4-6 hours on an empty stomach
- 2 tablets (10 mg) by oral route every 6 hours on an empty stomach
- 1 tablet (10 mg) by oral route every 6 hours on an empty stomach
- 2 tablets (10 mg) by oral route every 4 hours on an empty stomach
- 2 tablets (20 mg) by oral route every 6 hours on an empty stomach
- 2 tablets (20 mg) by oral route every 4 hours on an empty stomach
- 2 tablets (20 mg) by oral route every 4-6 hours on an empty stomach
- Depade
- naltrexone
- naltrexone microspheres
- Revia
- Vivitrol
Contraindicated
- sodium oxybate
- Xyrem
Severe
Moderate
- Acid Reducer (cimetidine)
- Acid Relief (cimetidine)
- Buprenex
- buprenorphine
- buprenorphine-naloxone
- butorphanol tartrate
- Butrans
- cimetidine
- Fanatrex
- gabapentin
- gabapentin enacarbil
- Gralise
- Gralise 30-day Starter Pack
- Heartburn Relief
- Horizant
- nalbuphine
- Neurontin
- Suboxone
- Tagamet Hb
- Zubsolv
- Sleep apnea
Contraindicated
- Acutely deteriorating asthma
- Alcohol intoxication
- Alcohol withdrawal delirium
- Benign prostatic hyperplasia
- Bradycardia
- Cardiac arrhythmia
- Coma
- Cor pulmonale
- Debilitation
- Dehydration
- Drug abuse
- Gastrointestinal tract surgery
- History of opioid overdose
- Hypotension
- Inflammatory bowel disease
- Intracranial hypertension
- Morbid obesity
- Neoplasm of brain
- Primary adrenocortical insufficiency
- Pulmonary emphysema
- Respiratory depression
- Seizure disorder
- Shock
- Suicidal ideation
- Systemic mastocytosis
- Toxic psychosis
- Ulcerative colitis
- Urethral stricture
- Urinary retention
Severe
Moderate
- Acute abdominal pain
- Biliary spasm
- Constipation
- Disease of liver
- Drug dependence
- Gallbladder disease
- Kidney disease with reduction in GFR
- Mood changes
- Untreated hypothyroidism
OXYMORPHONE HCL (oxymorphone HCl)
- Acute pain
- Edema
- Orthostatic hypotension
- Respiratory depression
- Visual changes
- Abdominal pain with cramps
- Anorexia
- CNS depression
- Constipation
- Diarrhea
- Dizziness
- Drowsy
- Dyspepsia
- Fatigue
- Fever
- Headache disorder
- Hyperhidrosis
- Hypotension
- Insomnia
- Lethargy
- Nausea
- Nervousness
- Pruritus of skin
- Syncope
- Vomiting
- Weight loss
- Xerostomia
More Frequent
Severe
Less Severe
- Acute confusion
- Hypoxia
- Abdominal distension
- Flatulence
- Tachycardia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Allergic dermatitis
- Altered mental status
- Blurred vision
- Bradycardia
- Dehydration
- Depression
- Disorder of adrenal gland
- Dysuria
- Hallucinations
- Hypersensitivity drug reaction
- Hypertension
- Ileus
- Miosis
- Palpitations
- Seizure disorder
- Severe dyspnea
- Urinary retention
Less Severe
- Agitation
- Clammy skin
- Drug-induced hot flash
- Dysphoric mood
- Dyspnea
- Erectile dysfunction
- Euphoria
- Flushing
- General weakness
- Infertility
- Libido changes
- Memory impairment
- Skin inflammation
- Urticaria
Contraindicated
Oxymorphone (Immed. Release, Inj)
Not recommended for use in pediatric patients. Potential increased sensitivity to effects, adverse CNS effects and risk for fatal respiratory depression. Safety and efficacy not established.
- 1 Day – 12 Years
- 1 Not recommended for use in pediatric patients. Potential increased sensitivity to effects, adverse CNS effects and risk for fatal respiratory depression. Safety and efficacy not established.
Severe Precaution
Oxymorphone (Immed. Release, Inj)
Not recommended for use in pediatric patients. Potential increased sensitivity to effects, adverse CNS effects and risk for fatal respiratory depression. Safety and efficacy not established.
- 12 Years – 18 Years
- Not recommended for use in pediatric patients. Potential increased sensitivity to effects, adverse CNS effects and risk for fatal respiratory depression. Safety and efficacy not established.
Management or Monitoring Precaution
None
Oxymorphone
- Severity Level:
2
- Additional Notes: Neonatal withdrawal/resp.depress. w/chronic or high dose; small teratogenic risk
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Oxymorphone
Insufficient data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Oxymorphone
General-Consider adding naloxone Rx. Pulmonary-Life threatening respiratory depression risk with high doses, cachexia, or debilitation due to altered pharmacokinetics (poor fat stores, muscle wasting, or altered clearance). Monitor closely at initiation and dose titration. Neuro/Psych-Risk for increased confusion and delirium. May increase fall risk. Avoid treatment with 3 or more CNS active drugs. Gastrointestinal-Constipation risk. Urogenital-Urinary retention risk.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | Y | Y | Y | Y | N |
BEERS: Y HEDIS: N STOPP: Y
No Known Risk
None
- Oxymorphone has a risk for abuse and addiction, which can lead to overdose and death. Oxymorphone may also cause severe, possibly fatal, breathing problems. To lower your risk, your doctor should have you take the smallest dose of oxymorphone that works, and take it for the shortest possible time.<br /><br />See also How to Use section for more information about addiction. The risk for severe breathing problems is higher when you start this medication and after a dose increase, or if you take the wrong dose/strength. Taking this medication with alcohol or other drugs that can cause drowsiness or breathing problems may cause very serious side effects, including death.<br /><br />Be sure you know how to take oxymorphone and what other drugs you should avoid taking with it. See also Drug Interactions section. Get medical help right away if any of these very serious side effects occur: slow/shallow breathing, unusual lightheadedness, severe drowsiness/dizziness, difficulty waking up.<br /><br /> Do not drink alcohol or take any products that contain alcohol while taking this medication. This may cause an increase of the medication in your body that may be fatal. Keep this medicine in a safe place to prevent theft, misuse, or abuse.<br /><br />If someone accidentally swallows this drug, get medical help right away. Before using this medication, women of childbearing age should talk with their doctor(s) about the risks and benefits. Tell your doctor if you are pregnant or if you plan to become pregnant.<br /><br /> During pregnancy, this medication should be used only when clearly needed. It may slightly increase the risk of birth defects if used during the first two months of pregnancy. Also, using it for a long time or in high doses near the expected delivery date may harm the unborn baby.<br /><br />To lessen the risk, take the smallest effective dose for the shortest possible time. Babies born to mothers who use this drug for a long time may develop severe (possibly fatal) withdrawal symptoms. Tell the doctor right away if you notice any symptoms in your newborn baby such as crying that doesn't stop, slow/shallow breathing, irritability, shaking, vomiting, diarrhea, poor feeding, or difficulty gaining weight.
| Acute pain | |
| G89.1 | Acute pain, not elsewhere classified |
| G89.11 | Acute pain due to trauma |
| G89.18 | Other acute postprocedural pain |
| 0-9 | A-Z |
|---|---|
| G89.1 | Acute pain, not elsewhere classified |
| G89.11 | Acute pain due to trauma |
| G89.18 | Other acute postprocedural pain |
Formulary Reference Tool